ABT vs MKL · P/E 25, rev $44.33B vs P/E 14, rev $7.57B
Abbott Laboratories (ABT) versus Markel Corporation (MKL) — a side-by-side from cached financials, not a winner call.
Abbott Laboratories (ABT) is a medical devices company listed on NYSE.
Markel Corporation (MKL) is a insurance - property & casualty company listed on US.
Latest reported ABT revenue for 2025-12-31 was $44.33B. Net income was $6.52B. Revenue was up 5.7% from 2024-12-31 to 2025-12-31. ABT currently screens at market cap $154.15B and trailing P/E 24.8.
Latest reported MKL revenue for 2026-06-30 was $7.57B. Net income was $956.5M. MKL currently screens at market cap $24.44B and trailing P/E 14.1.
ABT currently screens at market cap $154.15B and trailing P/E 24.8. MKL currently screens at market cap $24.44B and trailing P/E 14.1.
Not investment advice. Open the ABT and MKL stock pages for the full models.
Not investment advice.